Levobupivacine versus levobupivacine dexmedetomidine in thoracic paravertebral block for laparoscopic sympathectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201707002412282

Enrollment

Registered

2017-07-07

Start date

2016-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases Surgery palmer hyperhydrosis Anaesthesia

Interventions

Group L: Levobupivacaine group

Group LD: Levobupivacaine with dexmedetomidine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients (ASA I-II- III) aged 20-45 years submitted for unilateral laparoscopic thoracic sympathectomy due to palmer hyperhydrosis

Exclusion criteria

Exclusion criteria: Major systemic disease, chronic chest disease , chronic pain disorders, drug abuse, allergy to any medication included in the study protocol, any psychiatric disorder, coagulation or bleeding disorders, any contraindication to general anesthesia.

Design outcomes

Primary

Measure	Time frame
evaluate the postoperative pain by visual analogue pain score.	—

Secondary

Measure	Time frame
the timing of first rescue analgesia; total opioid consumption of fentanyl in 24 hours postoperatively	—

Countries

Egypt

Contacts

Public ContactAlaa elmaddawy

Lecturer

aaae72@gmail.com00201153304999

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026